15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Altimmune Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $10.00 to $20.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $13.50 sits 302% above the current $3.35. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 4 over recent months. On the fundamentals, the Street sees revenue growth near -89% this year and -100% next, consensus EPS building from about $-0.16 next quarter toward $-0.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Altimmune Inc.
As of Sep, 4 of 4 firms rate ALT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ALT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.20 – $-0.13 · 6 analysts · -41% YoY
Next period, 6 analysts expect Altimmune Inc to earn $-0.16 a share (range $-0.20 – $-0.13), versus $-0.27 a year earlier. Full-year consensus is $-0.59, growing to $-0.67 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts · -69% YoY
Revenue is expected to reach $0 (range $0 – $0), -69.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Altimmune Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALT.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$11.00+227.9% to target
Overall win rate
47%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$18.00+436.5% to target
Overall win rate
50%
+ Follow
#3
Roger Song
Jefferies · Rank #101
Buy
$28.00+734.6% to target
Overall win rate
43%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$25.00+645.2% to target
Overall win rate
33%
+ Follow
#5
Patrick R. Trucchio
HC Wainwright & Co. · Rank #230
Buy
$20.00+496.1% to target
Overall win rate
36%
+ Follow
ALT stock forecast FAQ
What is ALT's average 12-month price target?+
The 4 analysts with a live target average $13.50 for Altimmune Inc over the next 12 months, ranging from a $20.00 high to a $10.00 low.
Is ALT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ALT?+
The Street-high target is $20.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Leerink Partners). The average of all 4 active targets is $13.50.
How many Wall Street analysts cover ALT?+
4 analysts have an active rating on Altimmune Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ALT?+
Among analysts who currently cover ALT, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $11.00 target.
What is Altimmune Inc's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.20 – $-0.13) across 6 analysts. Full-year EPS is projected at $-0.59, rising to $-0.67 the following year.
How much revenue is Altimmune Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ALT lately?+
As of Sep, 4 of 4 firms rate ALT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
